NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xylo Bio

Xylo Bio

Private
Boulder, ColoradoHealthcare & Life Scienceshttps://xylo.bio/

Last Round

Grant

Oct 28, 2024

Total Funding Raised

$9.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Xylo Bio is a biotechnology company that develops targeted neuroplastogen therapies designed to rewire neural circuits and restore brain function for patients with psychiatric and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

neuroplastogenscomputational drug discoveryai drug discoverysmall molecule therapeuticsneurotherapeuticspsychedelic medicinenon-hallucinogenicdrug developmentmental health techvirtual screeningstructure-based designbiotechmolecular dockingpharma r&d

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xylo Bio Comps

Public and private peers based on sector, stage, and business model.

Xylo Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Xylo Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 28, 2024
SeedJun 3, 2024
SeedOct 1, 2022
AcceleratorOct 1, 2021

Key People

Founding team and executive leadership

Sam Banister

Co-founder and Chief Scientific Officer

Founding Team

Xylo Bio Investors

Notable investors and investment history

Xylo Bio investors
InvestorRounds
StartmateAccelerator
Main Sequence VenturesSeed
GaingelsSeed
Lionheart VenturesSeed
Negev CapitalSeed
Mystic VenturesSeed
Palo SantoSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 135% MoM, reaching 8.6K.

  • Oct 1, 2025

    Planning Phase I trials for neurotherapeutics with TGA and FDA.

Xylo Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xylo Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xylo Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoulder, Colorado
Employee Range31
Year Founded2021
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.